Everything below concerns metabolic research. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Major agencies have not authorized it for therapeutic use. |
| Anti-doping status | Prohibited in sport | Listed among peptide hormones and related substances. |
| Primary research area | Metabolic and body-composition effects | Studies often examine fat mass or lipid markers. |
| Human evidence | Limited and mixed | Public data do not establish clinical efficacy. |
| Analytical detection | LC-MS and immunoassays | Methods vary in sensitivity and validation. |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Actinidia chinensis var. deliciosa (kiwifruit) Ambrosia artemisiifolia (short ragweed) Ananas comosus (pineapple) Apium graveolens (celery) Arachis hypogaea (peanut) Artemisia vulgaris (mugwort) Betula verrucosa (European white birch) and Betula pendula (silver birch) Capsicum annuum (bell pepper) Chenopodium album (pigweed) Citrus sinensis (sweet orange) Corylus avellana (hazel) Cucumis melo (muskmelon) Daucus carota (carrot) Glycine max (soybean) Helianthus annuus (sunflower) Hevea brasiliensis (para rubber tree [latex]) Malus domestica (apple) Olea europaea (olive) Phleum pratense (timothy grass) Phoenix dactylifera (date palm) Prunus persica (peach) Pyrus communis (pear) Salsola kali (Russian thistle) Sinapis alba (yellow mustard) Solanum lycopersicum (tomato)
==== Branching and molecular conformation ==== The branching ratio of a polymer relates to the number of branch units in a randomly branched polymer and the number of arms in star-branched polymers and was defined by Zimm and Stockmayer as
== Atomic spectroscopy == Electrons exist in energy levels (i.e. atomic orbitals) within an atom. Atomic orbitals are quantized, meaning they exist as defined values instead of being continuous (see: atomic orbitals). Electrons may move between orbitals, but in doing so they must absorb or emit energy equal to the energy difference between their atom's specific quantized orbital energy levels. In optical spectroscopy, energy absorbed to move an electron to a higher energy level (higher orbital) and/or the energy emitted as the electron moves to a lower energy level is absorbed or emitted in the form of photons (light particles). Because each element has a unique number of electrons, an atom will absorb/release energy in a pattern unique to its elemental identity (e.g. Ca, Na, etc.) and thus will absorb/emit photons in a correspondingly unique pattern. The type of atoms present in a sample, or the amount of atoms present in a sample can be deduced from measuring these changes in light wavelength and light intensity. Atomic spectroscopy is further divided into atomic absorption spectroscopy and atomic emission spectroscopy. In atomic absorption spectroscopy, light of a predetermined wavelength is passed through a collection of atoms. If the wavelength of the source light has energy corresponding to the energy difference between two energy levels in the atoms, a portion of the light will be absorbed. The difference between the intensity of the light emitted from the source (e.g., lamp) and the light collected by the detector yields an absorbance value.
Fluphenazine acts primarily by blocking post-synaptic dopaminergic D2 and D1 receptors in the basal ganglia, cortical and limbic system. It also blocks α1 adrenergic receptors, muscarinic M1 receptors, and histaminergic H1 receptors, and like other phenothiazines, it competitively inhibits calmodulin. Fluphenazine depresses both the release of hypothalamic and hypophyseal hormones and the reticular activating system.
Enobosarm is not subject to this local transformation and potentiation, and so is theorized to have greatly reduced effects in these tissues relative to testosterone and certain other steroidal androgens. This is likewise theorized to be the case for non-5α-reductase-potentiated anabolic steroids like nandrolone and oxandrolone, which have high myotrophic–androgenic potency ratios in animals. The lack of 5α-reduction may result in reduced androgenic side effects like scalp hair loss, facial and body hair growth, and prostate growth. On the other hand, although SARMs, like enobosarm, as well as anabolic steroids, may have reduced virilizing effects in skin and hair follicles, this is not necessarily the case for virilization in general. In particular, the muscle-promoting effects of these agents can be considered a masculinizing effect. The potential masculinizing effects of enobosarm and SARMs in general are largely uncharacterized and unknown. Aside from metabolism differences related to 5α-reduction, enobosarm has also shown much greater impact in the liver, specifically on certain aspects of hepatic protein synthesis like reduction of sex hormone-binding globulin (SHBG) production, than even highly supraphysiological doses of parenteral testosterone. This phenomenon has also been seen with other SARMs, such as LGD-4033, as well as with synthetic orally active 17α-alkylated anabolic steroids like stanozolol.
Sources: en.wikipedia.org
Aqueous normal-phase chromatography (ANP) is a chromatographic technique that uses a polar stationary phase with a nonpolar mobile phase that contains water. It is "normal-phase" in the sense that polar analytes are retained by a polar stationary phase, but it differs from classical normal-phase chromatography in that the mobile phase contains water.
Flagella are rigid protein structures, about 20 nanometres in diameter and up to 20 micrometres in length, that are used for motility. Flagella are driven by the energy released by the transfer of ions down an electrochemical gradient across the cell membrane. Fimbriae (sometimes called "attachment pili") are fine filaments of protein, usually 2–10 nanometres in diameter and up to several micrometres in length. They are distributed over the surface of the cell, and resemble fine hairs when seen under the electron microscope. Fimbriae are believed to be involved in attachment to solid surfaces or to other cells, and are essential for the virulence of some bacterial pathogens. Pili (sing. pilus) are cellular appendages, slightly larger than fimbriae, that can transfer genetic material between bacterial cells in a process called conjugation where they are called conjugation pili or sex pili (see bacterial genetics, below). They can also generate movement where they are called type IV pili. Glycocalyx is produced by many bacteria to surround their cells, and varies in structural complexity: ranging from a disorganised slime layer of extracellular polymeric substances to a highly structured capsule. These structures can protect cells from engulfment by eukaryotic cells such as macrophages (part of the human immune system). They can also act as antigens and be involved in cell recognition, as well as aiding attachment to surfaces and the formation of biofilms. The assembly of these extracellular structures is dependent on bacterial secretion systems.
If RF value of a solution is zero, the solute remains in the stationary phase and thus it is immobile. If RF value = 1 then the solute has no affinity for the stationary phase and travels with the solvent front. For example, if a compound travels 9.9 cm and the solvent front travels 12.7 cm, the RF value = (9.9/12.7) = 0.779 or 0.78. RF value depends on temperature and the solvent used in experiment, so several solvents offer several RF values for the same mixture of compound. A solvent in chromatography is the liquid the paper is placed in, and the solute is the ink which is being separated.
Associated material may include field notes, drawings, photographs, spore prints, and permanent slide mounts, and the papers, labels, adhesives, and plastics used in storage are ideally archival quality to limit long-term deterioration. Historically, some curators prepared fleshy fungi as pressed longitudinal sections mounted on herbarium sheets and enclosed in packets, a method that saved space and could preserve gross form better than conventional box-dried specimens; additional dried fragments could be included for later microscopic study. For delicate, fragile, or deliquescent fungi, preservation has sometimes relied on dried sections or illustrations mounted on absorbent paper to retain at least some diagnostic morphological characters. For each specimen, records commonly include the collector, collection date, locality, identifier, later revisions, and notes on biotope and substrate. For newer specimens, locality data may include geographic coordinates so that collection sites can be revisited. In many collections, specimens are arranged alphabetically by genus and species and tracked in electronic collection databases. No single arrangement scheme is used in all fungaria: smaller collections may be arranged alphabetically by genus and species, whereas larger ones may place specimens in taxonomic order by major groups and then alphabetically within genera; within a species, material may also be arranged by host or geography to aid retrieval.
Electron transfer dissociation takes place in an ion trap mass spectrometer with an electrospray ionization source. The first ETD experiments at the University of Virginia utilized a radio frequency quadrupole linear ion trap (LQT) modified with a chemical ionization (CI) source at the back side of the instrument (see diagram at right). Because a spectrum can be obtained in about 300 milliseconds, liquid chromatography is often coupled with the ETD MS/MS. The disadvantage of using LQT is that the mass resolving power is less than that of other mass spectrometers. Subsequent studies have tried other instrumentation to improve mass resolution. Having a negative CI source at the back of the instrument interfered with the high-resolution analyzer in LQT-Orbitrap and quadrupole time-of-flight (QTOF), so alternate ionization methods for the radical anions have been introduced. In 2006 a group at Purdue University led by Scott McLuckey used a quadrupole/time-of-flight (QqTOF) tandem mass spectrometer with pulsed nano-ESI/atmospheric pressure chemical ionization (APCI) dual ionization source using radical anions of 1,3-dinitrobenzene as the electron donor. Later a lab at the University of Wisconsin adapted a hybrid quadrupole linear ion trap-orbitrap mass spectrometer to use ETD. This method also used a front-end ionization method for the radical anions of 9-anthracenecarboxylic acid via pulsed dual ESI sources.
Sources: en.wikipedia.org
No. It is not approved as a therapeutic drug by major regulators. It is sold for research purposes in many settings, which is not the same as clinical approval.
It is classified among peptide hormones and related substances that are prohibited in sport. The ban reflects anti-doping rules rather than a judgment that the peptide is effective for performance enhancement.
Human studies are limited and have not produced consistent evidence of meaningful clinical benefit. Some early trials examined metabolic endpoints, but larger confirmatory trials are generally lacking.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.